apricoxib
Small moleculeexperimental
Apricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID). It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer. It was also studied in clinical trials for non-small-cell lung cancer. Development was abandoned in 2015 due to poor clinical trial results. — Wikipedia
Clinical trial activity
7 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00569114)
Timeline
Indications
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1- Mol. weight
- 356.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaApricoxib ↗
- ChEMBLCHEMBL1835207 ↗
Also known as
- 2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1h-pyrrole
- apricoxib
- apricoxib
- apricoxib
- apricoxib
- apricoxib
- cs 706
- cs-706
- cs-706
- cs-706
- cs706 cpd
- r-109339
- r-109339
- tg01
- tg01
- tg01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02261714 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2012 | Hospital HM Universitario Sanchinarro, Queen Elizabeth Hospital NHS Foundation Trust, Targovax ASA, University of Liverpool, University of Manchester, University of Oslo |
| NCT01532362 | N/A | Nov 1, 2011 | University of California, Los Angeles |
| NCT00771953 | Phase 2 | Nov 1, 2008 | Adastra Pharmaceuticals, University of Maryland |
| NCT00709826 | Phase 2 | Aug 1, 2008 | Adastra Pharmaceuticals |
| NCT00657137 | Phase 2 | Apr 1, 2008 | Adastra Pharmaceuticals |
| NCT00652340 | Phase 2 | Apr 1, 2008 | Adastra Pharmaceuticals |
| NCT00569114 | Phase 1 | Oct 1, 2007 | Adastra Pharmaceuticals |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adastra Pharmaceuticals | For profit | 5 | 4 | 2 | 2007 |
| Hospital HM Universitario Sanchinarro | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Queen Elizabeth Hospital NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Targovax ASA | For profit | 1 | 1 | 1 | 2012 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Liverpool | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of Oslo | Academic/Hospital | 1 | 0 | 1 | 2012 |
9 organizations
Page 1 / 1